Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).
Renal Cell Carcinoma|Non-small Cell Lung Cancer|Pancreatic Adenocarcinoma|Colorectal Cancer|Ovarian Neoplasms
DRUG: RO7515629|DRUG: tocilizumab
Part 1, 2, 3: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Up to 15 months|Part 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs), From start of study treatment (cycle 0 day -7 or cycle 0 day -14) until two weeks after second or third RO7515629 infusion (cycle 1 day 1) for a total DLT window of up to 28 days.
Part 1, 2, 3: Pharmacokinetic Analysis: Maximum Serum Concentration (Cmax) of RO7515629, Up to 13 months|Part 1, 2, 3: Pharmacokinetic Analysis: Time of Maximum Serum Concentration (Tmax) of RO7515629, Up to 13 months|Part 1, 2, 3: Pharmacokinetic Analysis: Minimum Serum Concentration (Cmin) of RO7515629, Up to 13 months|Parts 1, 2, 3: Pharmacokinetic Analysis: Clearance (CL) of RO7515629, Up to 13 months|Part 1, 2, 3: Pharmacokinetic Analysis: Volume of Distribution at Steady State (Vss) of RO7515629, Up to 13 months|Part 1, 2, 3: Pharmacokinetic Analysis: Area Under The Curve (AUC) of RO7515629, Up to 13 months|Part 1, 2, 3: Number of Participants With RO7515629 Anti-drug Antibodies (ADAs), Up to 13 months|Part 1, 2, 3: Objective Response Rate (ORR), Up to approximately 18 months|Part 1, 2, 3: Disease Control Rate (DCR), Up to approximately 18 months|Part 1, 2, 3: Duration of Response (DoR), Up to approximately 18 months|Part 1, 2, 3: Progression Free Survival (PFS), Up to approximately 18 months|Part 1, 2, 3: Overall survival (OS), Defined as the time from first dose of study treatment to time of death., Up to approximately 18 months
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).